|
| 36928415 | Exhausted intratumoral Vδ2<sup>-</sup> γδ T cells in human kidney cancer retain effector function. | Nat Immunol | 2023 |
| 37544796 | CD4<sup>+</sup> T cells help myeloid-mediated killing of immune-evasive tumors. | Trends Cancer | 2023 |
| 37572314 | The Cancer Moonshot Immuno-Oncology Translational Network at 5: accelerating cancer immunotherapies. | J Natl Cancer Inst | 2023 |
| 36993558 | Analysis of evolutionary dynamics and clonal architecture in prostate cancer. | bioRxiv | 2023 |
| 37316414 | Impact of Squamous Histology on Clinical Outcomes and Molecular Profiling in Metastatic Urothelial Carcinoma Patients Treated With Immune Checkpoint Inhibitors or Enfortumab Vedotin. | Clin Genitourin Cancer | 2023 |
| 37286302 | Vaccinating against cancer: getting to prime time. | J Immunother Cancer | 2023 |
| 37208512 | Pembrolizumab alone and pembrolizumab plus chemotherapy in previously treated, extrapulmonary poorly differentiated neuroendocrine carcinomas. | Br J Cancer | 2023 |
| 37308118 | Early Liver Specialist Consultation is Associated With Faster Biochemical Resolution of Severe Immune Checkpoint Inhibitor-Induced Hepatitis. | J Natl Compr Canc Netw | 2023 |
| 37429923 | Biomarker-directed, pembrolizumab-based combination therapy in non-small cell lung cancer: phase 2 KEYNOTE-495/KeyImPaCT trial interim results. | Nat Med | 2023 |
| 37162860 | Tumor cell heterogeneity drives spatial organization of the intratumoral immune response in squamous cell skin carcinoma. | bioRxiv | 2023 |
| 37091148 | Somatic alterations of <i>TP53</i> and <i>MDM2</i> associated with response to enfortumab vedotin in patients with advanced urothelial cancer. | Front Oncol | 2023 |
| 36435709 | Serial stereotactic body radiation therapy for oligometastatic prostate cancer detected by novel PET-based radiotracers. | Urol Oncol | 2023 |
| 36931243 | Dynamic CD8<sup>+</sup> TÂ cell responses to cancer immunotherapy in human regional lymph nodes are disrupted in metastatic lymph nodes. | Cell | 2023 |
| 36593070 | Modulation of myeloid and T cells in vivo by Bruton's tyrosine kinase inhibitor ibrutinib in patients with metastatic pancreatic ductal adenocarcinoma. | J Immunother Cancer | 2023 |
| 34257408 | Safety and preliminary immunogenicity of JNJ-64041809, a live-attenuated, double-deleted Listeria monocytogenes-based immunotherapy, in metastatic castration-resistant prostate cancer. | Prostate Cancer Prostatic Dis | 2022 |
| 35373299 | ADXS31142 Immunotherapy ± Pembrolizumab Treatment for Metastatic Castration-Resistant Prostate Cancer: Open-Label Phase I/II KEYNOTE-046 Study. | Oncologist | 2022 |
| 35792807 | Agonizing over the Stimulatory Immune Checkpoint ICOS. | Clin Cancer Res | 2022 |
| 35420889 | Androgen conspires with the CD8<sup>+</sup> T cell exhaustion program and contributes to sex bias in cancer. | Sci Immunol | 2022 |
| 35419605 | Effect of Early Infant Probiotic Supplementation on Eczema, Asthma, and Rhinitis at 7 Years of Age. | Pediatrics | 2022 |
| 35389781 | Single-cell RNA-seq reveals cell type-specific molecular and genetic associations to lupus. | Science | 2022 |
| 36130508 | Circulating monocytes associated with anti-PD-1 resistance in human biliary cancer induce TÂ cell paralysis. | Cell Rep | 2022 |
| 36016626 | Editorial: Advancements in immunology and immunotherapy for breast cancer. | Front Oncol | 2022 |
| 36251389 | The 5-Hydroxymethylcytosine Landscape of Prostate Cancer. | Cancer Res | 2022 |
| 35321431 | APOBEC Mutational Signature and Tumor Mutational Burden as Predictors of Clinical Outcomes and Treatment Response in Patients With Advanced Urothelial Cancer. | Front Oncol | 2022 |
| 35247908 | Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials. | Clin Cancer Res | 2022 |
| 35176163 | A Phase Ib/II Study of the CDK4/6 Inhibitor Ribociclib in Combination with Docetaxel plus Prednisone in Metastatic Castration-Resistant Prostate Cancer. | Clin Cancer Res | 2022 |
| 35135866 | Next steps for clinical translation of adenosine pathway inhibition in cancer immunotherapy. | J Immunother Cancer | 2022 |
| 33420629 | Early changes in the circulating T cells are associated with clinical outcomes after PD-L1 blockade by durvalumab in advanced NSCLC patients. | Cancer Immunol Immunother | 2021 |
| 33678522 | Efficacy and Safety of Atezolizumab Plus Bevacizumab Following Disease Progression on Atezolizumab or Sunitinib Monotherapy in Patients with Metastatic Renal Cell Carcinoma in IMmotion150: A Randomized Phase 2 Clinical Trial. | Eur Urol | 2021 |
| 33541072 | Multi-Immune Agonist Nanoparticle Therapy Stimulates Type I Interferons to Activate Antigen-Presenting Cells and Induce Antigen-Specific Antitumor Immunity. | Mol Pharm | 2021 |
| 33539945 | Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE study. | Ann Oncol | 2021 |
| 33820953 | How to turn up the heat on the cold immune microenvironment of metastatic prostate cancer. | Prostate Cancer Prostatic Dis | 2021 |
| 33864502 | Tumor morphology and location associate with immune cell composition in pleomorphic sarcoma. | Cancer Immunol Immunother | 2021 |
| 33614400 | Non-radioactive and sensitive tracking of neutrophils towards inflammation using antibody functionalized magnetic particle imaging tracers. | Nanotheranostics | 2021 |
| 33753096 | Cross-platform comparison of immune-related gene expression to assess intratumor immune responses following cancer immunotherapy. | J Immunol Methods | 2021 |
| 33608377 | Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors. | J Immunother Cancer | 2021 |
| 34910940 | Cytotoxic CD4<sup>+</sup> TÂ cells in cancer: Expanding the immune effector toolbox. | Immunity | 2021 |
| 34906313 | Toward a better understanding of TÂ cells in cancer. | Cancer Cell | 2021 |
| 34729407 | In Vivo Measurement of Granzyme Proteolysis from Activated Immune Cells with PET. | ACS Cent Sci | 2021 |
| 34452927 | IL-7 expands lymphocyte populations and enhances immune responses to sipuleucel-T in patients with metastatic castration-resistant prostate cancer (mCRPC). | J Immunother Cancer | 2021 |
| 33986125 | Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancer. | J Immunother Cancer | 2021 |
| 33980590 | <i>TERT</i> promoter mutations and other prognostic factors in patients with advanced urothelial carcinoma treated with an immune checkpoint inhibitor. | J Immunother Cancer | 2021 |
| 34088740 | Attenuating CD3 affinity in a PSMAxCD3 bispecific antibody enables killing of prostate tumor cells with reduced cytokine release. | J Immunother Cancer | 2021 |
| 34003781 | Conditional Cancer Immunotherapy as a Safer Way to Step on the Gas. | Cancer Discov | 2021 |
| 34083417 | Deep immune profiling reveals targetable mechanisms of immune evasion in immune checkpoint inhibitor-refractory glioblastoma. | J Immunother Cancer | 2021 |
| 34304981 | A multidisciplinary team-based approach with lifestyle modification and symptom management to address the impact of androgen deprivation therapy in prostate cancer: A randomized phase II study. | Urol Oncol | 2021 |
| 34108181 | A Phase Ib Study of Atezolizumab with Radium-223 Dichloride in Men with Metastatic Castration-Resistant Prostate Cancer. | Clin Cancer Res | 2021 |
| 32343604 | Immune Checkpoint Blockade for Prostate Cancer: Niche Role or Next Breakthrough? | Am Soc Clin Oncol Educ Book | 2020 |
| 31732494 | Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer. | Cancer Discov | 2020 |
| 32059780 | Tissue Determinants of Human NK Cell Development, Function, and Residence. | Cell | 2020 |